U.S. Markets closed

Codexis, Inc. (CDXS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
25.49+0.27 (+1.07%)
At close: 4:00PM EDT
25.49 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close25.22
Open25.38
Bid24.50 x 1200
Ask28.00 x 800
Day's Range24.50 - 25.90
52 Week Range11.48 - 29.56
Volume347,626
Avg. Volume333,098
Market Cap1.644B
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-0.42
Earnings DateMay 06, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.50
  • Benzinga

    Codexis, Merck Extend Supply Pact For Enzyme Used To Manufacture Sitagliptin

    Codexis Inc (NASDAQ: CDXS) has amended and extended its agreement with Merck & Co Inc (NYSE: MRK) to license and supply a proprietary enzyme used to manufacture sitagliptin. Sitagliptin is an active pharmaceutical ingredient (API) in Merck's two anti-diabetic medications, Januvia and Janumet. Codexis and Merck leveraged Codexis' CodeEvolver enzyme engineering platform technology to design an enzyme to serve as a biocatalyst in the sitagliptin manufacturing process. In 2012 Codexis and Merck ente

  • GlobeNewswire

    Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin

    REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the amendment and extension of its agreement with Merck, known as MSD outside the United States and Canada, to license and supply a proprietary enzyme used in the manufacturing process for sitagliptin, the active pharmaceutical ingredient (API) in Merck’s JANUVIA® and one of the active ingredients in Merck’s JANUMET®. “Co

  • GlobeNewswire

    Codexis to Participate in Upcoming Virtual Healthcare Conferences

    REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in two upcoming virtual investment conferences. The H.C. Wainwright 23rd Annual Global Investment Conference — September 13, 2021 at 7:00 a.m. ET, on-demand corporate presentation The Cantor Virtual Global Healthcare Conference — September 28, 2021 at 10:40 a.m. ET, fireside chat Webc